A new framework for advancing in Drug-Induced Liver Injury research. The Prospective European DILI Registry. ...

BACKGROUND & AIMS No multi-national prospective study of drug-induced liver injury (DILI) has originated from Europe. The design of a prospective European DILI registry, clinical features and short-term outcomes of the cases and controls is reported. METHODS Patients with suspected DILI were pro...

Full description

Bibliographic Details
Main Authors: Björnsson, Einar S, Stephens, Camilla, Atallah, Edmond, Robles-Diaz, Mercedes, Alvarez-Alvarez, Ismael, Gerbes, Alexander, Weber, Sabine, Stirnimann, Guido, Kullak-Ublick, Gerd, Cortez-Pinto, Helena, Grove, Jane I, Lucena, M Isabel, Andrade, Raul J, Aithal, Guruprasad P
Format: Text
Language:unknown
Published: Wiley 2022
Subjects:
610 Medicine & health
Iceland
Online Access:https://dx.doi.org/10.48350/171634
https://boris.unibe.ch/171634/
Description
Summary:BACKGROUND & AIMS No multi-national prospective study of drug-induced liver injury (DILI) has originated from Europe. The design of a prospective European DILI registry, clinical features and short-term outcomes of the cases and controls is reported. METHODS Patients with suspected DILI were prospectively enrolled in the United Kingdom, Spain, Germany, Switzerland, Portugal, and Iceland, 2016-2021. DILI cases or non-DILI acute liver injury controls following causality assessment were enrolled. RESULTS Of 446 adjudicated patients, 246 DILI patients and 100 had acute liver injury due to other etiologies, mostly autoimmune hepatitis (n=42) and viral hepatitis (n=34). DILI patients (mean age 56 years), 57% women, 60% with jaundice and 3.6% pre-existing liver disease. DILI cases and non-DILI controls had similar demographics, clinical features, and outcomes. A single agent was implicated in 199 (81%) DILI cases. Amoxicillin-clavulanate, flucloxacillin, atorvastatin, nivolumab/ipilimumab, infliximab and ...

Similar Items